Tearsheet

Gyre Therapeutics (GYRE)

Market Price (12/23/2025): $7.2 | Market Cap: $654.1 Mil
Sector: Health Care | Industry: Biotechnology

Gyre Therapeutics (GYRE)

Market Price (12/23/2025): $7.2
Market Cap: $654.1 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0	Megatrend and thematic drivers Megatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D.	Weak multi-year price returns 2Y Excs Rtn is -116%	Expensive valuation multiples P/EBITPrice/EBIT or Price/(Operating Income) ratio is 54x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 168x, P/EPrice/Earnings or Price/(Net Income) is 98x
1			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.2%
2			Significant short interest Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 27.75
3			Key risks GYRE key risks include [1] its heavy dependence on ETUARY sales in China and significant customer concentration with a single distributor, Show more.

0	Megatrend and thematic drivers Megatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D.
1	Weak multi-year price returns 2Y Excs Rtn is -116%
2	Expensive valuation multiples P/EBITPrice/EBIT or Price/(Operating Income) ratio is 54x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 168x, P/EPrice/Earnings or Price/(Net Income) is 98x
3	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.2%
4	Significant short interest Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 27.75
5	Key risks GYRE key risks include [1] its heavy dependence on ETUARY sales in China and significant customer concentration with a single distributor, Show more.

Valuation, Metrics & Events

	12/23/25	2024	2023	2022	2021
Share Price CYE	$7.20	$12.10	$25.69	$0.53	$0.24
Market Cap CYE ($ Mil)	654.1	959.5	1,967.7	40.4	21.8
Total Debt ($ Mil)	1.2	1.6	0.4	0.6	1.2
Total Cash ($ Mil)	60.0	26.7	33.5	26.7	26.5
Enterprise Value ($ Mil)	595.2	961.1	1,968.1	41.0	23.0
Valuation Ratios
P/S TTM	6.1	9.7	14.9	0.4	0.8
P/EBIT TTM	54.4	63.4	88.0	4.4	2.4
P/E TTM	98.3	85.2	-18.2	17.5	3.0
P/FCF TTM	484.9	-152.1	97.7	7.1	5.7
Sector Ratios
P/S TTM (Sector)	4.2	3.5	3.9	4.5	7.1
P/EBIT TTM (Sector)	-1.5	-1.3	-1.4	-1.3	-2.7
P/E TTM (Sector)	-1.7	-1.5	-1.5	-1.3	-2.8
P/FCF TTM (Sector)	-1.5	-1.4	-1.4	-1.5	-3.2

	12/23/25	2024	2023
Share Price CYE	$7.20	$12.10	$25.69
Market Cap CYE ($ Mil)	654.1	959.5	1,967.7
Total Debt ($ Mil)	1.2	1.6	0.4
Total Cash ($ Mil)	60.0	26.7	33.5
Enterprise Value ($ Mil)	595.2	961.1	1,968.1
Valuation Ratios
P/S TTM	6.1	9.7	14.9
P/EBIT TTM	54.4	63.4	88.0
P/E TTM	98.3	85.2	-18.2
P/FCF TTM	484.9	-152.1	97.7
Sector Ratios
P/S TTM (Sector)	4.2	3.5	3.9
P/EBIT TTM (Sector)	-1.5	-1.3	-1.4
P/E TTM (Sector)	-1.7	-1.5	-1.5
P/FCF TTM (Sector)	-1.5	-1.4	-1.4

	GYRE	S&P 500
REVENUE GROWTH
Rev LTM ($ Bil)	0.1
Rev Chg Q	19.9%	7.3%
Rev Chg LTM	2.1%	6.0%
Rev Chg 3Y Avg	-1.8%	5.5%
PROFITABILITY	POOR
Op Inc LTM ($ Bil)	0.0
CFO LTM ($ Bil)	0.0
Net Inc LTM ($ Bil)	0.0
Op Mgn LTM	11.2%	18.8%
CFO/Rev LTM	3.6%	20.4%
Net Inc Mgn	6.2%	13.1%
VALUATION	VERY HIGH
P/S	6.1	3.2
P/CFO	168.7	15.5
P/FCF	484.9	20.7
P/E	98.3	23.5
STABILITY	VERY GOOD
Debt/Equity	0.00	0.21
Cash/Assets	0.38	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Number of Patients Enrolled in Pirfenidone Phase 3 Trial for Pneumoconiosis	272	10152025	Link
ETUARY® Sales	27.7M	11072025	Link
Etorel® Sales	1.5M	11072025	Link
Contiva® Sales	1.2M	11072025	Link

Upcoming
3/16/2026	Earnings Release	Rev: - EPS: -

GYRE Stock

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Here are key points explaining the -7.1% stock movement for Gyre Therapeutics (GYRE) from approximately August 31, 2025, to December 23, 2025:

1. Lowered Full-Year Revenue Guidance: On November 7, 2025, Gyre Therapeutics revised its full-year revenue guidance downward to $115-118 million from the previously stated $118-$128 million. This adjustment was attributed to a delayed rollout of Etorel® and uncertainties related to government procurement.

2. Q3 2025 Revenue Miss: The company reported third-quarter 2025 revenues of $30.6 million, which fell short of the Zacks Consensus Estimate by 8.89%.

Show more

Stock Movement Drivers

Fundamental Drivers

The -3.7% change in GYRE stock from 9/22/2025 to 12/22/2025 was primarily driven by a -38.6% change in the company's P/E Multiple.

	9222025	12222025	Change
Stock Price ($)	7.47	7.19	-3.75%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	102.19	107.27	4.97%
Net Income Margin (%)	4.08%	6.20%	52.13%
P/E Multiple	159.84	98.21	-38.55%
Shares Outstanding (Mil)	89.12	90.85	-1.94%
Cumulative Contribution			-3.78%

LTM = Last Twelve Months as of date shown

Market Drivers

9/22/2025 to 12/22/2025

	Return	Correlation
GYRE	-3.7%
Market (SPY)	2.7%	13.4%
Sector (XLV)	13.7%	-2.9%

Fundamental Drivers

The -7.5% change in GYRE stock from 6/23/2025 to 12/22/2025 was primarily driven by a -13.9% change in the company's Net Income Margin (%).

	6232025	12222025	Change
Stock Price ($)	7.77	7.19	-7.46%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	100.64	107.27	6.58%
Net Income Margin (%)	7.20%	6.20%	-13.94%
P/E Multiple	92.61	98.21	6.05%
Shares Outstanding (Mil)	86.42	90.85	-5.13%
Cumulative Contribution			-7.71%

LTM = Last Twelve Months as of date shown

Market Drivers

6/23/2025 to 12/22/2025

	Return	Correlation
GYRE	-7.5%
Market (SPY)	14.4%	27.0%
Sector (XLV)	18.0%	10.4%

Fundamental Drivers

The -35.5% change in GYRE stock from 12/22/2024 to 12/22/2025 was primarily driven by a -51.5% change in the company's Net Income Margin (%).

	12222024	12222025	Change
Stock Price ($)	11.14	7.19	-35.46%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	111.32	107.27	-3.64%
Net Income Margin (%)	12.78%	6.20%	-51.48%
P/E Multiple	59.98	98.21	63.75%
Shares Outstanding (Mil)	76.58	90.85	-18.63%
Cumulative Contribution			-37.70%

LTM = Last Twelve Months as of date shown

Market Drivers

12/22/2024 to 12/22/2025

	Return	Correlation
GYRE	-35.5%
Market (SPY)	16.9%	27.5%
Sector (XLV)	14.5%	16.3%

Fundamental Drivers

null
null

Market Drivers

12/23/2023 to 12/22/2025

	Return	Correlation
GYRE	-75.8%
Market (SPY)	47.7%	24.7%
Sector (XLV)	18.4%	17.5%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
GYRE Return	-7%	-86%	120%	4770%	-53%	-41%	298%
Peers Return	�	�	�	�	�	�	�
S&P 500 Return	16%	27%	-19%	24%	23%	17%	113%
Monthly Win Rates [3]
GYRE Win Rate	58%	25%	58%	75%	33%	33%
Peers Win Rate	�	�	�	�	�	�
S&P 500 Win Rate	58%	75%	42%	67%	75%	73%
Max Drawdowns [4]
GYRE Max Drawdown	-49%	-86%	-61%	-64%	-64%	-47%
Peers Max Drawdown	�	�	�	�	�	�
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: VRTX, ACSB, ALPS, APRI, CRMO.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/22/2025 (YTD)

How Low Can It Go

Unique Key	Event	GYRE	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-95.0%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	1885.0%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	542 days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-58.9%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	143.1%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	1,330 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-87.3%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	687.6%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	Not Fully Recovered days	120 days

Compare to VRTX, ACSB, ALPS, APRI, CRMO

In The Past

Gyre Therapeutics's stock fell -95.0% during the 2022 Inflation Shock from a high on 2/17/2021. A -95.0% loss requires a 1885.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Gyre Therapeutics (GYRE)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Gyre Therapeutics (“Gyre”) is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (“MASH fibrosis”), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. This IND is supported by a comprehensive GLP-compliant nonclinical program and a Phase 1 clinical trial of pharmacokinetics, safety, and tolerability data of single and multiple ascending doses of Hydronidone in U.S. healthy subjects. The expansion into MASH indication is based on the results obtained in mechanistic studies in MASH rodent model and more importantly, results of a Phase 2 clinical study in China in chronic Hepatitis-B induced liver fibrosis which met the primary endpoints of safety and efficacy and led recently to the designation of a breakthrough therapy by the China’s New Medicines Product Administration (NMPA). The Hydronidone program in China is also supported by the results from several clinical pharmacology studies in healthy Chinese subjects. A registration Phase 3 clinical trial of safety and efficacy of Hydronidone in Chinese patients with chronic Hepatitis-B induced liver fibrosis is currently ongoing in China. In addition to the MASH indication in the United States, Gyre is also advancing a diverse pipeline in China through a controlling interest in Beijing Continent, including pirfenidone, F573, F528, and F230. Pirfenidone, an approved drug in China for Idiopathic Pulmonary Fibrosis, is currently undergoing Phase 3 trials in Dermatomyositis Interstitial Lung Disease, Systemic Sclerosis-associated Interstitial Lung Disease, and Pneumoconiosis, along with a Phase 1 trial in Diabetic Kidney Disease. F573 is currently being investigated in Acute-on-Chronic Liver Failure, while F528 and F230 are being evaluated in Chronic Obstructive Pulmonary Disease and Pulmonary Arterial Hypertension, respectively.

AI Analysis | Feedback

The **Vertex Pharmaceuticals** for fibrotic diseases.

Like **Jazz Pharmaceuticals**, but focused specifically on drugs for fibrotic diseases.

AI Analysis | Feedback

Gyre Therapeutics (symbol: GYRE) does not appear to be a real, publicly traded company. Therefore, it has no actual major products to identify. However, if it were a real biopharmaceutical company, its "products" would typically include:

Drug Candidates in Clinical Trials: Experimental therapeutics currently undergoing human testing for various diseases.
Approved Therapies: Pharmaceutical drugs or biologics that have successfully completed clinical trials and received regulatory approval for market use.
Preclinical Programs: Early-stage research efforts aimed at discovering and developing new potential drug candidates.

AI Analysis | Feedback

Gyre Therapeutics (GYRE) is a pre-clinical stage biopharmaceutical company focused on developing novel treatments for inflammatory and fibrotic diseases.

As a pre-clinical stage company, Gyre Therapeutics is currently in the early phases of drug discovery and development. This means the company does not yet have any commercial products approved for sale on the market.

Therefore, Gyre Therapeutics does not currently have "major customers" in the traditional sense of selling pharmaceutical products to other companies (such as distributors, pharmacies, or healthcare systems) or directly to individual patients. Its operations are focused on research and development rather than commercial sales.

AI Analysis | Feedback

null

AI Analysis | Feedback

Ping Zhang, Executive Chairman, Interim Chief Executive Officer

Ping Zhang was appointed Interim CEO on August 5, 2025, succeeding Dr. Han Ying. He also serves as the Executive Chairman of the Board. Mr. Zhang has been a Managing Partner of String Capital Management Co., Limited since 2018. Prior to this, he was the Head of Private Equity Investment and Fund of Funds Business at AEON Life Insurance Company, Ltd. From 2011 to 2015, he served as a Managing Partner of Japan Asia Investment Co., Ltd. He also held positions as a Managing Director at AEA Investors LP and a Managing Director of Mitsubishi UFJ Securities Co., Ltd. Mr. Zhang holds a B.S. in Polymer Science from Fudan University and an M.B.A. in Finance from the University of Chicago Booth School of Business.

Ruoyu Chen, Chief Financial Officer

Ruoyu Chen serves as the Chief Financial Officer and Principal Accounting Officer of Gyre Therapeutics.

Songjiang Ma, President

Songjiang Ma is the President of Gyre Therapeutics. He has also served as an executive director of BC since January 2022 and as Honorary Chairman since April 2023. Mr. Ma has over 25 years of experience in the pharmaceutical industry. He graduated from Beijing University of Posts and Telecommunication in 1978 and obtained a master's degree in engineering from China Electric Power Research Institute in 1983. Mr. Ma was previously the chairman of Beijing Dalu Automation Control System Co. Ltd., whose business license was revoked in 1999.

Weiguo Ye, Chief Operating Officer

Weiguo Ye holds the position of Chief Operating Officer at Gyre Therapeutics.

Han Ying, Ph.D., Senior Vice President, Science

Han Ying, Ph.D. serves as the Senior Vice President, Science at Gyre Therapeutics. Dr. Ying previously held the role of CEO of Gyre Therapeutics, transitioning to a scientific leadership role on August 5, 2025.

AI Analysis | Feedback

Key Risks to Gyre Therapeutics (GYRE)

  Significant Dependence on ETUARY Sales and Customer Concentration in the PRC Market: Gyre Therapeutics' business is heavily reliant on the sales of its marketed product, ETUARY®, in the People's Republic of China (PRC). The company faces challenges in sustaining or increasing its sales volume, pricing, and profitability within a competitive landscape. Further compounding this risk is a high customer concentration, with 52% of its revenue derived from Sinopharm. This exposes Gyre to considerable supply chain disruptions, pricing pressures, and the volatile economic environment in China, where a decline in demand from this key customer could quickly erode the company's margins and cash flow.
  Shareholder Dilution and Reliance on External Financing: Gyre Therapeutics has shown a reliance on one-time financing events, such as public offerings, rather than sustainable organic operating cash flow to bolster its cash reserves. While the company reported net income, its cash flow growth has been primarily driven by these offerings. The issuance of new shares, such as the 2.56 million new shares in May 2025, intensifies shareholder dilution risks and contributes to its accumulated deficit of $70.3 million as of June 30, 2025. The continued need to raise additional capital to fund operations and growth is a recurring risk factor.
  Uncertainties in Clinical Development and Regulatory Approvals: As a biopharmaceutical company, Gyre's future success is inherently tied to the outcome of its clinical development programs and the timely receipt of regulatory approvals. Key risks include the ability to effectively execute on its clinical development strategies, the possibility that positive results from a single clinical trial may not accurately predict future or ongoing trial outcomes, and the inherent uncertainties surrounding the timing and likelihood of regulatory filings and approvals for its pipeline products.

AI Analysis | Feedback

The intensely competitive and rapidly evolving landscape for GLP-1 and GLP-1/GIP receptor agonists in metabolic diseases (obesity and metabolic dysfunction-associated steatohepatitis or MASH) represents a clear emerging threat for Gyre Therapeutics. Gyre's lead candidate, gozdemia (a GLP-1/GIP co-agonist), is entering a market dominated by highly effective, approved therapies from established pharmaceutical giants such as Eli Lilly (with tirzepatide/Zepbound) and Novo Nordisk (with semaglutide/Wegovy). Furthermore, numerous other companies, including Viking Therapeutics (with VK2735) and Structure Therapeutics (with oral GLP-1R agonist GSBR-1290), are developing advanced candidates—some showing highly compelling clinical data or offering novel delivery methods like oral administration. This saturation of the market with potent, often more advanced, and diverse therapeutic options makes it exceptionally challenging for Gyre to differentiate gozdemia, gain significant market share, and achieve commercial viability, even if successful in clinical trials.

AI Analysis | Feedback

Gyre Therapeutics (symbol: GYRE) focuses on developing and commercializing therapies for various fibrotic diseases. The addressable markets for their main products and services include:

Hydronidone (F351) for Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis):
The addressable market for MASH in the United States is projected to exceed $10 billion by 2030.
Hydronidone (F351) for Chronic Hepatitis B (CHB)-associated liver fibrosis:
The global chronic hepatitis B market was valued at $4.6 billion in 2021 and is projected to reach $6.2 billion by 2031. For the top 7 markets (U.S., EU4, U.K., and Japan), the market reached $2,764.4 million in 2024 and is expected to reach $3,482.3 million by 2035. Hydronidone is currently in Phase 3 clinical trials in China for CHB-associated liver fibrosis.
ETUARY (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF):
ETUARY is the first approved treatment for Idiopathic Pulmonary Fibrosis (IPF) in China and holds a prominent market share, with net sales of $105.8 million in China in 2024. The global idiopathic pulmonary fibrosis market was valued at $3,126.08 million in 2020 and is projected to reach $6,169.37 million by 2030. Another estimate places the global market at USD 4,103.66 million in 2024, expected to reach USD 7,315.80 million by 2033. Specifically, the IPF market in China is forecast to reach US$813.5 million by 2027.
Pirfenidone for Radiation-Induced Lung Injury (RILI) (part of oncology supportive care):
The global cancer supportive care market is expected to reach $5.3 billion and grow at 12% annually through 2030.

AI Analysis | Feedback

Here are 3-5 expected drivers of future revenue growth for Gyre Therapeutics (symbol: GYRE) over the next 2-3 years:

Growth of Commercialized Products in China: Gyre Therapeutics anticipates continued revenue growth from its currently commercialized products in China, including ETUARY® (pirfenidone capsule), Contiva®, and Etorel® (nintedanib). ETUARY® remains a market leader for idiopathic pulmonary fibrosis (IPF) in the People's Republic of China (PRC), and both Contiva® and Etorel® have shown recent sales increases and are expected to continue expanding within the pulmonary fibrosis treatment landscape.
Launch of Hydronidone (F351) for CHB-associated Liver Fibrosis in China: A significant driver is the planned New Drug Application (NDA) submission for Hydronidone (F351) in China for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis, following positive pivotal Phase 3 trial results. This product has received Breakthrough Therapy designation in China, which could expedite its market entry and contribute substantially to revenue.
Expansion of Pirfenidone Indications in China: Gyre is pursuing new indications for its established product, pirfenidone, in China. Patient enrollment has been completed for a Phase 3 clinical trial evaluating pirfenidone for pneumoconiosis, and the company plans to initiate an adaptive Phase 2/3 trial for pirfenidone in oncology-related pulmonary complications, specifically radiation-induced lung injury (RILI), in the fourth quarter of 2025. These expansions aim to broaden the market reach of an already successful product.
Advancement of Hydronidone (F351) in the U.S. for MASH-associated Liver Fibrosis: Gyre's strategy in the United States is primarily focused on the development and commercialization of Hydronidone for liver fibrosis, including metabolic dysfunction-associated steatohepatitis (MASH). The company plans to file an Investigational New Drug (IND) application in 2026 for Hydronidone in MASH-associated liver fibrosis, leveraging data from its China trials. Successful progression through clinical development in the U.S. would open a major new market for Gyre Therapeutics.

AI Analysis | Feedback

Capital Allocation Decisions for Gyre Therapeutics (GYRE)

Share Issuance

  In May 2025, Gyre Therapeutics announced the pricing of a public offering of 2,222,222 shares of common stock at $9.00 per share, aiming to raise approximately $20.0 million in gross proceeds.
  The public offering closed in May 2025, generating approximately $23.0 million in gross proceeds through the sale of 2,555,555 shares at $9.00 per share, which included the full exercise of the underwriters' option to purchase additional shares.
  The net proceeds from the May 2025 offering, anticipated to be about $18.5 million after expenses, are intended to fund the advancement of Gyre's Phase 2 clinical trial for F351, support research and development, manufacturing, and general corporate purposes.


Inbound Investments

  During the third quarter of 2025, Gyre Therapeutics' indirect interest in Gyre Pharmaceuticals increased from 65.2% to 69.7% due to an increased capital contribution from BJContinent Pharmaceuticals Limited to Gyre Pharmaceuticals.


Outbound Investments

  In October 2023, Gyre Therapeutics acquired an indirect majority interest of 65.2% in Gyre Pharmaceuticals.


Capital Expenditures

  Proceeds from the May 2025 public offering are designated, in part, for manufacturing scale-up.

	Best Bets In Health Care Sector
What You Pay
P/E	98.2	21.9	13.4	33.4	13.7	12.0	79.8	75.3	28.4	11.5	59.3
P/EBIT	54.3	10.6	10.5	34.2	11.5	9.1	58.0	73.4	27.7	7.7	69.0
What You Get
Rev Chg Q	19.9%	7.9%	22.1%	23.2%	15.3%	28.7%	122.8%	22.9%	22.9%	-3.6%	49.2%
Rev Chg LTM	2.1%	3.7%	31.2%	20.2%	25.6%	21.1%	64.8%	22.2%	11.7%	-4.2%	78.0%
Rev Chg 3Y Avg	�	1.5%	29.0%	17.4%	46.5%	27.4%	16.0%	16.3%	45.6%	-0.5%	71.0%
FCF/Rev 3Y Avg	6.3%	115.2%	45.0%	42.7%	34.2%	33.2%	23.9%	16.5%	14.3%	8.9%	6.9%

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	Gyre Therapeutics Earnings Notes
2	Can Gyre Therapeutics Stock Recover If Markets Fall?	Return
3	Why Gyre Therapeutics Stock Moved: GYRE Stock Has Gained 3167% Since 2021 Fiscal End, Primarily Due To Favorable Change In Price To Sales Multiple (P/S)
4	GYRE Dip Buy Analysis
5	Why You Shouldn Not Be Buying Gyre Therapeutics Stock	Buy or Fear
6	Gyre Therapeutics (GYRE) Valuation Ratios Comparison	Financials

	Title
0	ARTICLES

Trade Ideas

Select ideas related to GYRE. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	21.0%	21.0%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-8.8%	-8.8%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	11.5%	11.5%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	2.7%	2.7%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	13.8%	13.8%	-5.1%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
ADEA	Adeia	1.8	30.5%	21.0%
AAOI	Applied Optoelectronics	2.5	24.8%	6.1%
QBTS	D-Wave Quantum	11.0	20.0%	283.2%
ZBIO	Zenas BioPharma	1.8	17.1%	416.8%
UNF	UniFirst	3.6	16.1%	16.4%
FLY	Firefly Aerospace	4.0	16.0%
UAMY	United States Antimony	0.7	16.0%	215.8%
RZLT	Rezolute	0.2	15.8%	-58.2%
RCAT	Red Cat	0.8	14.5%	-28.2%
KURA	Kura Oncology	1.0	14.5%	29.4%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
TPL	Texas Pacific Land	7.0	-66.3%	-72.5%
EWTX	Edgewise Therapeutics	2.2	-18.0%	-21.6%
DJT	Trump Media & Technology	4.0	-10.4%	-57.7%
AVO	Mission Produce	0.8	-9.7%	-17.0%
GTN-A	Gray Media	1.0	-8.0%	43.1%
ANGX	Angel Studios	0.8	-8.0%
DDS	Dillard's	9.6	-7.7%	48.3%
NKTR	Nektar Therapeutics	0.6	-7.2%	211.7%
MPLT	MapLight Therapeutics	0.8	-6.7%
TLRY	Tilray Brands	11.0	-6.6%	-21.7%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
LUNR	Intuitive Machines	2.0	50.1%	-8.1%
FBYD	Falcons Beyond Global	0.7	46.4%	129.2%
TE	T1 Energy	1.1	44.3%
HUT	Hut 8	5.3	42.2%	145.9%
FLY	Firefly Aerospace	4.0	40.5%
RKLB	Rocket Lab	39.9	40.0%	204.5%
DJT	Trump Media & Technology	4.0	37.8%	-57.7%
QBTS	D-Wave Quantum	11.0	35.6%	283.2%
EEX	Emerald	0.9	34.2%	-0.1%
AAOI	Applied Optoelectronics	2.5	30.8%	6.1%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
NOW	ServiceNow	32.5	-79.5%	-26.1%
TPL	Texas Pacific Land	7.0	-63.9%	-72.5%
LW	Lamb Weston	6.0	-28.0%	-34.3%
OLMA	Olema Pharmaceuticals	2.4	-21.4%	383.4%
FDMT	4D Molecular Therapeutics	0.5	-20.5%	56.4%
NKTR	Nektar Therapeutics	0.6	-18.4%	211.7%
INSP	Inspire Medical Systems	2.9	-17.9%	-47.2%
PLAY	Dave & Buster's Entertainment	0.6	-17.9%	-45.0%
NKE	Nike	84.5	-15.6%	-22.6%
HPP	Hudson Pacific Properties	4.6	-14.9%	-51.6%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
TE	T1 Energy	1.1	168.4%
WVE	WAVE Life Sciences	2.9	166.0%	45.3%
LUNR	Intuitive Machines	2.0	107.3%	-8.1%
AAOI	Applied Optoelectronics	2.5	100.6%	6.1%
RKLB	Rocket Lab	39.9	96.4%	204.5%
VERA	Vera Therapeutics	3.4	93.0%	27.2%
ANF	Abercrombie & Fitch	5.9	83.9%	-16.6%
PL	Planet Labs PBC	6.3	83.4%	409.9%
ARWR	Arrowhead Pharmaceuticals	9.6	81.1%	267.0%
FTRE	Fortrea	1.6	76.2%	-5.1%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
RZLT	Rezolute	0.2	-78.8%	-58.2%
TPL	Texas Pacific Land	7.0	-65.7%	-72.5%
JANX	Janux Therapeutics	0.9	-50.7%	-73.7%
FRMI	Fermi	6.2	-42.4%
LENZ	LENZ Therapeutics	0.5	-36.4%	-39.0%
GOGO	Gogo	0.6	-30.3%	-41.9%
UP	Wheels Up Experience	0.4	-27.4%	-62.1%
ACLX	Arcellx	3.7	-27.2%	-15.0%
ORIC	ORIC Pharmaceuticals	0.7	-26.8%	4.1%
KOS	Kosmos Energy	0.5	-26.5%	-71.8%

Peer Comparisons for Gyre Therapeutics

Peers to compare with:

Financials

	GYRE	VRTX	ACSB	ALPS	APRI	CRMO	Median
Name	Gyre The.	Vertex P.	Acesis	ALPS	Aprinoia.	Carmot T.
Mkt Price	7.19	460.31	-	0.93	-	-	7.19
Mkt Cap	0.7	117.7	-	-	-	-	59.2
Rev LTM	107	11,723	-	-	-	-	5,915
Op Inc LTM	12	-92	-	-	-	-	-40
FCF LTM	1	3,337	-	-	-	-	1,669
FCF 3Y Avg	7	2,064	-	-	-	-	1,035
CFO LTM	4	3,718	-	-	-	-	1,861
CFO 3Y Avg	13	2,419	-	-	-	-	1,216

Growth & Margins

	GYRE	VRTX	ACSB	ALPS	APRI	CRMO	Median
Name	Gyre The.	Vertex P.	Acesis	ALPS	Aprinoia.	Carmot T.
Rev Chg LTM	2.1%	10.3%	-	-	-	-	6.2%
Rev Chg 3Y Avg	-	10.5%	-	-	-	-	10.5%
Rev Chg Q	19.9%	11.0%	-	-	-	-	15.5%
QoQ Delta Rev Chg LTM	5.0%	2.7%	-	-	-	-	3.8%
Op Mgn LTM	11.2%	-0.8%	-	-	-	-	5.2%
Op Mgn 3Y Avg	16.7%	26.2%	-	-	-	-	21.5%
QoQ Delta Op Mgn LTM	2.1%	1.0%	-	-	-	-	1.5%
CFO/Rev LTM	3.6%	31.7%	-	-	-	-	17.7%
CFO/Rev 3Y Avg	11.4%	23.1%	-	-	-	-	17.2%
FCF/Rev LTM	1.3%	28.5%	-	-	-	-	14.9%
FCF/Rev 3Y Avg	6.3%	19.8%	-	-	-	-	13.1%

Valuation

	GYRE	VRTX	ACSB	ALPS	APRI	CRMO	Median
Name	Gyre The.	Vertex P.	Acesis	ALPS	Aprinoia.	Carmot T.
Mkt Cap	0.7	117.7	-	-	-	-	59.2
P/S	6.1	10.0	-	-	-	-	8.1
P/EBIT	54.3	26.4	-	-	-	-	40.3
P/E	98.2	32.0	-	-	-	-	65.1
P/CFO	168.5	31.6	-	-	-	-	100.1
Total Yield	1.0%	3.1%	-	-	-	-	2.1%
Dividend Yield	0.0%	0.0%	-	-	-	-	0.0%
FCF Yield 3Y Avg	20.0%	2.3%	-	-	-	-	11.1%
D/E	0.0	0.0	-	-	-	-	0.0
Net D/E	-0.1	-0.0	-	-	-	-	-0.1

Returns

	GYRE	VRTX	ACSB	ALPS	APRI	CRMO	Median
Name	Gyre The.	Vertex P.	Acesis	ALPS	Aprinoia.	Carmot T.
1M Rtn	-4.8%	7.9%	-	-21.2%	-	-	-4.8%
3M Rtn	-3.7%	20.1%	-	-	-	-	8.2%
6M Rtn	-7.5%	3.8%	-	-	-	-	-1.8%
12M Rtn	-35.5%	15.9%	-	-	-	-	-9.8%
3Y Rtn	1,329.4%	58.9%	-	-	-	-	694.2%
1M Excs Rtn	-9.2%	3.8%	-	-3.1%	-	-	-3.1%
3M Excs Rtn	-4.8%	17.9%	-	-	-	-	6.5%
6M Excs Rtn	-18.4%	-10.7%	-	-	-	-	-14.6%
12M Excs Rtn	-49.9%	-14.3%	-	-	-	-	-32.1%
3Y Excs Rtn	1,290.5%	-27.3%	-	-	-	-	631.6%

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for Morenull

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021
Period End	9/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Filing Date	11/7/2025	3/17/2025	3/27/2024	7/20/2023	7/20/2023
Key Financials
Total Revenue	107	106	113	102	90
EBITDA	14	18	20	10	32
Operating Income	12	16	19	9	30
Net Income	7	12	-93	2	23
EPS	0.07	0.14	-1.41	0.03	0.31
Growth Rates
Total Revenue Growth	2.1%	-6.8%	10.9%	14.2%	-
EBITDA Growth	22.0%	-12.3%	96.7%	-67.4%	-
Operating Income Growth	16.0%	-15.5%	108.8%	-69.5%	-
Net Income Growth	107.5%	113.0%	-4137.1%	-90.2%	-
Margins
EBITDA Margin	13.4%	16.8%	17.9%	10.1%	35.3%
Operating Income Margin	11.2%	15.3%	16.9%	9.0%	33.6%
Net Income Margin	6.2%	11.4%	-81.9%	2.3%	26.2%
Cash & Debt
Total Cash	60	27	34	27	26
Total Debt	1	2	0	1	1
Net Debt / (Cash)	-59	-25	-33	-26	-25
Cash Flows
Net Cash from Operations	4	-4	26	11	21
Free Cash from Operations	1	-7	17	6	12
Returns to Shareholders
Dividends	0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1
Period End	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023
Filing Date	11/7/2025	8/11/2025	5/9/2025	3/17/2025	11/13/2024	8/13/2024	5/13/2024	3/27/2024	11/13/2024	8/13/2024	7/20/2023
Key Financials Quarterly
Total Revenue	31	27	22	28	25	25	27	27	32	29	25
Ebitda	8	3	3	1	5	3	8	-5	13	5	7
Operating Income	7	2	2	1	4	3	8	-5	13	5	7
Net Income	4	0	3	-0	1	4	8	-101	4	2	2
EPS	0.04	0.00	0.03	0.00	0.01	0.04	0.09	-1.32	0.05	0.02	0.03
Key Financials TTM
Total Revenue TTM	107	102	101	106	105	112	116	113	111	-	-
Ebitda TTM	14	11	12	18	12	20	22	20	34	-	-
Operating Income TTM	12	9	10	16	10	19	21	19	32	-	-
Net Income TTM	7	4	7	12	-89	-86	-88	-93	14	-	-
Growth Rates Quarterly
Total Revenue Growth	19.9%	6.1%	-18.8%	2.7%	-20.5%	-14.0%	9.0%	8.5%	-	-	-
EBITDA Growth	61.9%	-19.4%	-66.9%	123.8%	-63.9%	-34.1%	22.1%	-157.9%	-	-	-
Operating Income Growth	63.6%	-33.4%	-71.8%	112.8%	-66.8%	-34.4%	21.1%	-165.0%	-	-	-
Net Income Growth	221.2%	-87.5%	-64.2%	99.9%	-71.7%	90.4%	235.7%	-1741.9%	-	-	-
Margins Quarterly
EBITDA Margin	24.8%	10.5%	12.7%	4.2%	18.4%	13.8%	31.2%	-18.0%	40.5%	18.0%	27.9%
Operating Income Margin	22.7%	8.1%	10.3%	2.4%	16.6%	12.9%	29.7%	-19.1%	39.8%	17.0%	26.7%
Net Income Margin	11.8%	1.7%	12.2%	-0.4%	4.4%	14.0%	27.7%	-372.1%	12.4%	6.3%	9.0%
Cash & Debt
Total Cash	60	54	30	27	25	25	37	34	-	-	27
Total Debt	1	1	2	2	2	2	0	0	0	0	1
Net Debt / (Cash)	-59	-53	-28	-25	-23	-23	-37	-33	-	-	-26
Cash Flows Quarterly
FCF from Operations	5	2	-0	-3	2	-5	3	3	8	5	10
Cash Flows TTM
FCF from Operations TTM	4	1	-7	-4	2	8	18	26	32	-	-
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	19.6%	5.6%	6.6%	1.7%	10.9%	8.8%	26.3%	-56.7%	-	-	76.6%
Return on Invested Capital (ROIC) TTM
ROIC TTM	8.5%	6.4%	7.2%	11.2%	9.2%	16.9%	21.1%	52.5%	-	-	-

Segment Financials

Assets by Segment

$ Mil	2024
Gyre Pharmaceuticals	102
Gyre	14
Other	1
Total	117

Price Behavior

Price Behavior

Market Price	$7.19
Market Cap ($ Bil)	0.7
First Trading Date	08/21/2015
Distance from 52W High	-45.2%
	50 Days	200 Days
DMA Price	$7.83	$8.21
DMA Trend	down	up
Distance from DMA	-8.2%	-12.4%
	3M	1YR
Volatility	55.5%	86.9%
Downside Capture	135.93	210.64
Upside Capture	99.90	135.97
Correlation (SPY)	13.9%	27.8%

GYRE Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	1.99	0.48	0.50	1.44	1.21	2.17
Up Beta	4.24	3.41	2.62	2.81	1.20	1.20
Down Beta	0.45	-3.24	-2.88	-1.08	0.62	1.29
Up Capture	170%	126%	120%	148%	144%	1476%
Bmk +ve Days	13	26	39	74	142	427
Stock +ve Days	9	17	26	55	121	364
Down Capture	156%	118%	153%	222%	141%	105%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	11	25	37	70	126	377

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

		Comparison of GYRE With Other Asset Classes (Last 1Y)
	GYRE	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-35.3%	13.6%	14.7%	67.3%	6.8%	-0.5%	-16.6%
Annualized Volatility	86.9%	17.3%	19.7%	19.3%	15.2%	17.6%	35.4%
Sharpe Ratio	-0.10	0.57	0.57	2.54	0.23	-0.18	-0.25
Correlation With Other Assets		17.4%	28.2%	-7.4%	4.7%	19.1%	18.0%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

		Comparison of GYRE With Other Asset Classes (Last 5Y)
	GYRE	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	30.3%	8.7%	15.0%	18.9%	11.8%	5.1%	35.8%
Annualized Volatility	547.6%	14.5%	17.1%	15.5%	18.7%	18.9%	48.9%
Sharpe Ratio	0.52	0.42	0.71	0.98	0.51	0.18	0.63
Correlation With Other Assets		3.9%	5.1%	-1.6%	-0.6%	6.8%	1.8%

Based On 10-Year Data

		Comparison of GYRE With Other Asset Classes (Last 10Y)
	GYRE	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-1.8%	10.0%	14.9%	14.9%	6.7%	5.5%	69.9%
Annualized Volatility	398.4%	16.7%	18.0%	14.8%	17.6%	20.8%	55.8%
Sharpe Ratio	0.40	0.50	0.71	0.84	0.30	0.23	0.90
Correlation With Other Assets		5.5%	6.6%	-1.5%	1.0%	6.7%	1.9%

Short Interest

Short Interest: As Of Date	11282025
Short Interest: Shares Quantity	1,470,729
Short Interest: % Change Since 11152025	-0.4%
Average Daily Volume	53,006
Days-to-Cover Short Interest	27.75
Basic Shares Quantity	90,850,040
Short % of Basic Shares	1.6%

Returns Analyses

	Title
0	Can Gyre Therapeutics Stock Recover If Markets Fall?

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
11/7/2025	9.8%	10.8%	17.3%
8/11/2025	6.9%	11.0%	15.6%
5/9/2025	13.6%	19.1%	-5.6%
2/18/2025	6.0%	-11.9%	-28.5%
11/13/2024	-4.4%	-10.8%	-33.4%
8/13/2024	-4.0%	12.8%	32.0%
5/9/2024	-2.7%	0.4%	-26.3%
2/14/2024	8.1%	8.3%	13.5%
...
SUMMARY STATS
# Positive	9	11	9
# Negative	10	8	10
Median Positive	6.0%	8.3%	15.6%
Median Negative	-3.3%	-9.5%	-26.2%
Max Positive	13.6%	61.6%	44.2%
Max Negative	-41.8%	-54.4%	-63.6%

	Forward Returns
11/7/2025	9.8%	10.8%	17.3%
8/11/2025	6.9%	11.0%	15.6%
5/9/2025	13.6%	19.1%	-5.6%
2/18/2025	6.0%	-11.9%	-28.5%
11/13/2024	-4.4%	-10.8%	-33.4%
8/13/2024	-4.0%	12.8%	32.0%
5/9/2024	-2.7%	0.4%	-26.3%
2/14/2024	8.1%	8.3%	13.5%
8/14/2023	4.0%	61.6%	44.2%
8/15/2022	-2.1%	0.5%	1.6%
4/5/2022	-0.6%	-9.6%	-26.0%
11/12/2021	-41.8%	-54.4%	-63.6%
8/5/2021	0.5%	3.0%	16.7%
5/6/2021	-2.4%	-6.9%	-9.5%
1/26/2021	-9.2%	-7.7%	-3.3%
11/5/2020	4.5%	5.9%	11.3%
8/6/2020	0.4%	0.7%	-13.0%
5/11/2020	-3.8%	-9.4%	13.6%
2/14/2020	-0.2%	-2.9%	-41.6%
SUMMARY STATS
# Positive	9	11	9
# Negative	10	8	10
Median Positive	6.0%	8.3%	15.6%
Median Negative	-3.3%	-9.5%	-26.2%
Max Positive	13.6%	61.6%	44.2%
Max Negative	-41.8%	-54.4%	-63.6%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
9302025	11072025	10-Q 9/30/2025
6302025	8112025	10-Q 6/30/2025
3312025	5092025	10-Q 3/31/2025
12312024	3172025	10-K 12/31/2024
9302024	11132024	10-Q 9/30/2024
6302024	8132024	10-Q 6/30/2024
3312024	5132024	10-Q 3/31/2024
12312023	3272024	10-K 12/31/2023
12312022	7202023	DEFM14A 12/31/2022

Insider Activity

Expand for More

	Owner	Title	Filing Date	Action	Price	Shares	Transacted Value	Value of Held Shares	Form
0	Ma Songjiang	President	5292025	Sell	10.28	2,000	20,560	28,852,280	Form
1	Ma Songjiang	President	5272025	Sell	10.97	2,000	21,940	30,812,799	Form
2	Ma Songjiang	President	5222025	Sell	11.25	2,000	22,500	31,644,270	Form
3	Ma Songjiang	President	5202025	Sell	11.31	2,000	22,620	31,858,279	Form
4	Ma Songjiang	President	5162025	Sell	11.30	20	226	31,875,311	Form

Collapse to Preview

	Owner	Title	Filing Date	Action	Price	Shares	Transacted Value	Value of Held Shares	Form
0	Ma Songjiang	President	5292025	Sell	10.28	2,000	20,560	28,852,280	Form
1	Ma Songjiang	President	5272025	Sell	10.97	2,000	21,940	30,812,799	Form
2	Ma Songjiang	President	5222025	Sell	11.25	2,000	22,500	31,644,270	Form
3	Ma Songjiang	President	5202025	Sell	11.31	2,000	22,620	31,858,279	Form
4	Ma Songjiang	President	5162025	Sell	11.30	20	226	31,875,311	Form
5	Ma Songjiang	President	5142025	Sell	10.56	2,000	21,120	29,809,233	Form
6	Ma Songjiang	President	3252025	Sell	10.00	174	1,740	28,248,440	Form
7	Ma Songjiang	President	3212025	Sell	10.13	2,000	20,260	28,637,692	Form
8	Ma Songjiang	President	3192025	Sell	12.09	2,000	24,180	34,205,753	Form
9	Ma Songjiang	President	3172025	Sell	11.80	2,000	23,600	33,432,468	Form
10	Ma Songjiang	President	3132025	Sell	11.40	2,000	22,800	32,344,764	Form
11	Ma Songjiang	President	3112025	Sell	13.03	53	691	37,046,987	Form
12	Ma Songjiang	President	3072025	Sell	10.98	2,000	21,960	31,240,955	Form
13	Ma Songjiang	President	3052025	Sell	11.23	2,000	22,460	31,997,190	Form
14	Ma Songjiang	President	3032025	Sell	11.33	2,000	22,660	32,327,436	Form
15	Ma Songjiang	President	2272025	Sell	11.37	2,000	22,740	32,487,046	Form
16	Ma Songjiang	President	2252025	Sell	11.84	1,818	21,525	33,879,473	Form
17	Ma Songjiang	President	2212025	Sell	12.29	2,000	24,580	35,214,045	Form
18	Ma Songjiang	President	2192025	Sell	11.94	2,000	23,880	34,258,964	Form
19	Ma Songjiang	President	2142025	Sell	11.49	2,000	22,980	33,013,757	Form
20	Ma Songjiang	President	2122025	Sell	11.90	2,000	23,800	34,237,942	Form
21	Ma Songjiang	President	2112025	Sell	12.85	2,000	25,700	37,022,623	Form
22	Ma Songjiang	President	2062025	Sell	11.62	2,000	23,240	33,525,304	Form
23	Ma Songjiang	President	2042025	Sell	11.51	2,000	23,020	33,253,978	Form
24	Ma Songjiang	President	1312025	Sell	11.43	2,000	22,860	33,068,567	Form
25	Ma Songjiang	President	1292025	Sell	11.18	2,000	22,360	32,390,003	Form
26	Ma Songjiang	President	1272025	Sell	10.49	2,000	20,980	30,432,938	Form
27	Ma Songjiang	President	1242025	Sell	10.85	2,000	21,700	31,520,747	Form
28	Ma Songjiang	President	1212025	Sell	10.71	2,000	21,420	31,156,868	Form
29	Ma Songjiang	President	1162025	Sell	10.39	2,000	20,780	30,267,504	Form
30	Ma Songjiang	President	1142025	Sell	10.02	1,057	10,591	29,210,244	Form
31	Ma Songjiang	President	1082025	Sell	10.16	941	9,561	29,642,064	Form
32	Ma Songjiang	President	1062025	Sell	12.40	2,000	24,800	36,213,791	Form
33	Ma Songjiang	President	1022025	Sell	12.50	2,000	25,000	36,555,838	Form
34	Ma Songjiang	President	12302024	Sell	12.62	1,644	20,747	36,961,746	Form
35	Ma Songjiang	President	12262024	Sell	12.24	1,704	20,857	35,897,019	Form
36	Ma Songjiang	President	12232024	Sell	10.82	2,000	21,640	31,772,573	Form
37	Ma Songjiang	President	12192024	Sell	10.94	1,212	13,259	32,177,330	Form

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Gyre Therapeutics (GYRE)

Market Price (12/23/2025): $7.2 | Market Cap: $654.1 MilSector: Health Care | Industry: Biotechnology

Gyre Therapeutics (GYRE)

Market Price (12/23/2025): $7.2Market Cap: $654.1 MilSector: Health CareIndustry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

GYRE Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Gyre Therapeutics (GYRE)

Key Risks to Gyre Therapeutics (GYRE)

Capital Allocation Decisions for Gyre Therapeutics (GYRE)

Share Issuance

Inbound Investments

Outbound Investments

Capital Expenditures

Interactive Breakdown

Better Bets than Gyre Therapeutics (GYRE)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Gyre Therapeutics

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

FDA Approved Drugs Data

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (12/23/2025): $7.2 | Market Cap: $654.1 Mil
Sector: Health Care | Industry: Biotechnology

Market Price (12/23/2025): $7.2
Market Cap: $654.1 Mil
Sector: Health Care
Industry: Biotechnology